All the Drug Class Drugs
Kinase Inhibitor. encorafenib 75 mg. Hard Caps.180 x 75 mg
BRAF V600E or V600K Mutation-Positive Unresectable or Metast. Melanoma and for BRAF V600E Mutation-Positive Metast. Non-Small Cell Lung Cancer (NSCLC)- recommended dosage is 450 mg (six 75 mg caps.) orally 1 X d in combin. with binimetinib until dis. progress. or unacceptable tox.
BRAF V600E Mutation-Positive Metast. Colorectal Cancer (CRC)- recommended dosage is 300 mg (four 75 mg capsules) orally 1 X d in combin. with cetuximab until dis. progress. or unacceptable tox.
For adults with:
BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma or
BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)- as detected by an approved test, after prior ther.
BRAF V600E Mutation-Positive metastatic non-small cell lung cancer (NSCLC)- in combin. with binimetinib, when mutation detected by an approved test.
C/I: Hypersens.
EGFR Inhibitor, Kinase Inhibitor. Vandetanib 100 mg. FC TABS: 30 x 100mg. Recom.
dose 300mg 1x dly. Pts. must be given
patient alert card and be informed of
risks Assess QTc interval prior to init.
tmt. Can reduce dosage if necess.
See lit.
Tmt. aggressive and sympt. medullary
thyroid cancer (MTC) in pts. with
unresectable locally advanced or
metastatic dis. Pts.in whom Rearranged
during Transfection (RET) mutation is not
known or is neg., a possible lower benefit
should be taken into account. See lit.
C/I: Hypersens. to active subst. or excip;
congenital long QTc syndrome; pts. with
QTc interval > 480msec.; concomit. use
of arsenic, cisapride,erythromycin, iv.
toremifene, mizolastine moxifloxacin,
class Ia and III antiarrhythmics. See lit.
Kinase Inhibitor. lazertinib 80 mg, 240 mg. FC Tabs.:60 X 80mg/ 14/28/30 X 240 mg
Recomm. dose:240 mg orally once/d in combin. with amivantamab until dis. progress. or unacceptable tox.Ffirst-line tmt. of adults with locally adv. or metast. non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitut. mutat., as detected by an approved test, in combin. with amivantamab
C/I: Hypersens.
Kinase Inhibitor. binimetinib 15 mg. FC Tab. 180X 15 mg
Recommended dosage is 45 mg orally taken twice daily, approx. 12 hs. apart, in combin. with encorafenib until dis. progress. or unacceptable tox.
BRAF V600E or V600K Mutation-Posit. Unresectable or Metast. Melanoma in combin. with encorafenib.
BRAF V600E Mutation-Posit. metast. non-small cell lung cancer (NSCLC) adenocarcinoma in combin. with encorafenib.
C/I:Hypersens.
Kinase Inhibitor. momelotinib dihydrochloride 100 mg, 150 mg, 200 mg. FC Tab 30 X 100,150,200 mg
Daily dose: 200 mg. Not to be used with other JAK inhib. CBC and liver function to be tested before and during tmt.
Tmt. of intermediate or high-risk myelofibrosis (MF), including prim. MF or sec. MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
C/I: Hypersens. Pregn. and lactat
